ITMCTR2200005511
Not yet recruiting
Phase 4
Suhuang antitussive capsule in the treatment of bronchial asthma--a multi-center, randomized, double-blind, placebo-controlled clinical study
ConditionsBronchial Asthma
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Bronchial Asthma
- Sponsor
- Shanghai General Hospital
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •(1\) Outpatients with chronic persistent of asthma who meet the typical asthma diagnostic criteria in the 2020 edition of the Guidelines for the Prevention and Treatment of Bronchial Asthma;
- •(2\) The severity is graded as mild or moderate, and the ACT score is \=19 points;
- •(3\) Age from 18 to 60 years old;
- •(4\) Sign the informed consent form.
- •Those who meet all the above criteria at the same time can be included in the study.
Exclusion Criteria
- •(1\) Combined use of compound methoxyphenamine capsules, codeine tablets, codeine oral solution, compound pseudoephedrine hydrochloride oral solution, tabellae dextpomethorphani hydrobromiditablets, compound licorice tablets, Jizhi syrup, Shedan Chuanbei loquat ointment, Xianzhuli Oral Liquid, Qutanling Oral Liquid, Qutan Zhike capsules, Fei Li Ke Mixture, Xuanfei Zhisou Mixture and other medicines containing anti\-cough ingredients, or Maxing Zhike Tablets, Gejie Dingchuan Pills and other Chinese traditional medicines containing ephedra ingredients within 2 weeks;
- •(2\) Patients with a history of arrhythmia, coronary atherosclerotic heart disease, hypertension or hyperthyroidism, and poor control;
- •(3\) Patients with severe heart, liver, kidney, brain, mental, or neurological diseases;
- •(4\) Allergic to drugs known in this study;
- •(5\) Pregnant or lactating women or those planning pregnancy;
- •(6\) Those who have participated in or are participating in other clinical trials within 28 days;
- •(7\) Those who are deemed unsuitable to participate in this trial by the researcher.
- •Those who meet any of the above criterion cannot be included in this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Budenofalk granules and capsules in the treatment of Crohn's diseaseCrohn's disease, budesonide, Budenofalk, IBD, ziekte van CrohnNL-OMON24660Dr. Falk Pharma Benelux B.V.138
Not yet recruiting
Phase 4
Effect of Wuling caspule on adolescent with mild to moderate anxiety and depression stateMild to moderate anxiety and depressionITMCTR2000004117Huzhou Hospital of Traditional Chinese Medici
Recruiting
Phase 4
Efficacy and safety of Wuling capsule in the treatment of early Parkinson's disease with mild depression: a multicenter, randomized, double-blind, placebo-controlled studyITMCTR2100004821Xinhua Hospital, Affiliated to Shanghai Jiaotong University, School of Medicine
Not yet recruiting
Phase 1
Clinical study on hot compressing of herbal medicine to prevent and treat nocturiaITMCTR2200006617Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine
Active, not recruiting
Phase 1
Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Emergency Departmentvaso-occlusive crisis due to sickle cell diseaseMedDRA version: 20.0Level: LLTClassification code: 10072397Term: Vaso-occlusive crisis Class: 10005329Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]CTIS2023-504847-15-00Assistance Publique Hopitaux De Paris915